URGN · UroGen Pharma Ltd
United States · RS rating 56 · As of 2026-11-03
| Price | 34.40 USD |
|---|---|
| 1-day change | +0.1% |
| RS rating (overall / 1M / 3M / 12M) | 56 / 22 / 25 / 90 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 45 / 29 / 45 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +21.7% |
| Sales growth Q/Q | +37.7% |
| Distance from 52-week high | +31.6% |
| Market cap (USD) | $1.2B |